Prevalence of autoimmune disease among patients with lung cancer: Implications for immunotherapy treatment options

JAMA Oncology

Volumn 2, Issue 11, 2016, Pages 1507-1508

  Khan, Saad A ^a,b   Pruitt, Sandi L ^b   Xuan, Lei ^b   Gerber, David E ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EFFECTS; AGED; AUTOIMMUNE DISEASES; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; PREVALENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; FEMALE; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; PREVALENCE;

EID: 85013046049     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.2238     Document Type: Letter

References (4)

1. PostowMA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006-2017.
2. February 11th, 2016; Available from: http://www.aarda.org/autoimmune-information/autoimmune-statistics.
3. Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100(5):822-828.
4. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol. 2016;2(2):234-240.